Pharma deal potentially great news, but there are worries over funding
Daniel Elkeles responds to the UK-US pharmaceuticals deal.
Responding to the announcement of the UK-US pharmaceuticals deal, the chief executive of NHS Providers, Daniel Elkeles, said:
"This deal is potentially very good news for patients, for the NHS and for UK life sciences.
"It is great that NHS patients will have increased access to groundbreaking new treatments.
"The announcement also builds on the longstanding close partnership between the NHS and the pharmaceutical industry, making this the best place in the world to carry out clinical trials.
"However it is not yet clear how it will be paid for.
"There is absolutely no slack in current published NHS spending plans for this major commitment and that is a real worry for trust leaders."
Related articles
- Training

NHS finance for senior leaders
3 March 20279:30 - 16:00Online
Develop a greater understanding of NHS financial principles, funding flows and reporting to strengthen your confidence to effectively contribute at board level.
Leadership
Finance
- Network

NHS Chief Finance Officers and Commercial Leaders Forum
2 December 202610:00 - 11:30Online
An opportunity for NHS finance and commercial leaders to connect in a safe space, share strategic reflections, and explore national leadership priorities together.
Finance
- Conference

The NHS and Youth Participation Conference
19 November 202610:00 - 16:00In-person
Delivering the Milburn Review: How the NHS can create opportunity, improve health and strengthen local economies
Health inequalities
Improvement
Leadership
Mental health
Prevention
Workforce